Valuation: Rezolute Inc

Market Cap 536M 469M 432M 400M 759M 51.15B 772M 5.18B 2.03B 25.12B 2.01B 1.97B 87.01B P/E 2026 *
-7.33x
P/E 2027 * -7.89x
Enterprise Value 536M 469M 432M 400M 759M 51.15B 772M 5.18B 2.03B 25.12B 2.01B 1.97B 87.01B EV / Sales 2026 *
-
EV / Sales 2027 * 233x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute Inc

Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-14.41% - - 518M
-0.38%-3.44%+71.35%+128.83% 56.71B
+4.91%-0.19%+73.70%+92.14% 51.3B
+1.48%+5.97%+22.59%+495.47% 25.26B
-0.59%-4.68%-16.82%-12.99% 23.65B
+4.43%+3.25%+50.89%+2.05% 18.69B
+2.01%+2.99%+40.72%-24.93% 17.71B
-6.84%+2.18%+203.03%+348.11% 17.7B
+5.89%+2.30%+52.03% - 14.26B
+1.76%+2.24%+29.57%+195.70% 14.1B
Average +1.45%+2.46%+58.56%+153.05% 26.6B
Weighted average by Cap. +1.61%+0.75%+60.26%+145.51%

Financials

2026 *2027 *
Net sales - 2.3M 2.02M 1.86M 1.72M 3.26M 220M 3.32M 22.26M 8.73M 108M 8.65M 8.46M 374M
Net income -72.7M -63.6M -58.65M -54.26M -103M -6.94B -105M -702M -275M -3.41B -273M -267M -11.8B -75.12M -65.71M -60.6M -56.07M -106M -7.17B -108M -726M -284M -3.52B -282M -276M -12.2B
Net Debt - -
Logo Rezolute Inc
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-